Cite
Serum cytokeratin 19 fragment 21‐1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease.
MLA
Nakamura, Y., et al. “Serum Cytokeratin 19 Fragment 21‐1 and Carcinoembryonic Antigen Combination Assay as a Biomarker of Tumour Progression and Treatment Response in Extramammary Paget Disease.” British Journal of Dermatology, vol. 181, no. 3, Sept. 2019, pp. 535–43. EBSCOhost, https://doi.org/10.1111/bjd.17789.
APA
Nakamura, Y., Tanese, K., Hirai, I., Amagai, M., Kawakami, Y., & Funakoshi, T. (2019). Serum cytokeratin 19 fragment 21‐1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease. British Journal of Dermatology, 181(3), 535–543. https://doi.org/10.1111/bjd.17789
Chicago
Nakamura, Y., K. Tanese, I. Hirai, M. Amagai, Y. Kawakami, and T. Funakoshi. 2019. “Serum Cytokeratin 19 Fragment 21‐1 and Carcinoembryonic Antigen Combination Assay as a Biomarker of Tumour Progression and Treatment Response in Extramammary Paget Disease.” British Journal of Dermatology 181 (3): 535–43. doi:10.1111/bjd.17789.